SEC Comment Letter 0000000000-24-006315 to Starling Oncology, Inc. (TOI)
Starling Oncology, Inc.
Date: June 3, 2024 · CIK: 0001799191 · Accession: 0000000000-24-006315
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39248
Letter
United States securities and exchange commission logo June 3, 2024 Mihir Shah Chief Financial Officer Oncology Institute, Inc. 18000 Studebaker Road, Suite 800 Cerritos , California 90703 Re:Oncology Institute, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 Filed March 28, 2024 File No. 001-39248 Dear Mihir Shah: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services
Show Raw Text
United States securities and exchange commission logo
June 3, 2024
Mihir Shah
Chief Financial Officer
Oncology Institute, Inc.
18000 Studebaker Road, Suite 800
Cerritos , California 90703
Re:Oncology Institute, Inc.
Form 10-K for Fiscal Year Ended December 31, 2023
Filed March 28, 2024
File No. 001-39248
Dear Mihir Shah:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services